These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24994118)

  • 1. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.
    Vanden Borre P; Gunda V; McFadden DG; Sadow PM; Varmeh S; Bernasconi M; Parangi S
    Oncotarget; 2014 Jun; 5(12):3996-4010. PubMed ID: 24994118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
    Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
    Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
    Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
    Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.
    Nehs MA; Nucera C; Nagarkatti SS; Sadow PM; Morales-Garcia D; Hodin RA; Parangi S
    Endocrinology; 2012 Feb; 153(2):985-94. PubMed ID: 22202162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
    Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
    Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combinatorial Strategy for Targeting
    Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
    Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src inhibitors in suppression of papillary thyroid carcinoma growth.
    Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
    Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
    Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
    Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.
    Nehs MA; Nagarkatti S; Nucera C; Hodin RA; Parangi S
    Surgery; 2010 Dec; 148(6):1154-62; discussion 1162. PubMed ID: 21134546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination
    Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
    Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
    [No Abstract]   [Full Text] [Related]  

  • 13. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
    Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
    Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors.
    Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Muzza M; Capelli V; Latrofa F; Persani L; Chiovato L; Rotondi M
    Sci Rep; 2019 Mar; 9(1):4390. PubMed ID: 30867499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways.
    Baquero P; Jiménez-Mora E; Santos A; Lasa M; Chiloeches A
    Mol Carcinog; 2016 Nov; 55(11):1639-1654. PubMed ID: 26392228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
    Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
    Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
    Tsai J; Lee JT; Wang W; Zhang J; Cho H; Mamo S; Bremer R; Gillette S; Kong J; Haass NK; Sproesser K; Li L; Smalley KS; Fong D; Zhu YL; Marimuthu A; Nguyen H; Lam B; Liu J; Cheung I; Rice J; Suzuki Y; Luu C; Settachatgul C; Shellooe R; Cantwell J; Kim SH; Schlessinger J; Zhang KY; West BL; Powell B; Habets G; Zhang C; Ibrahim PN; Hirth P; Artis DR; Herlyn M; Bollag G
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3041-6. PubMed ID: 18287029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.
    Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
    Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.